Table 1. Expression of integrin αvβ3 on tumor microvessels is associated with poor prognostic markers in patients with stage 3 neuroblastoma.
| No. of patients (%) | Mean % microvessels expressingαvβ3 (95% confidence interval) | P-value from t-test or ANOVA | |
|---|---|---|---|
| MYCN | |||
| Non-amplified | 37 (69%) | 34% (26% – 42%) | < 0.001 |
| Amplified | 17 (31%) | 68% (57% – 79%) | |
| Shimada Classification | |||
| Favorable | 23 (43%) | 28% (20% – 36%) | < 0.001 |
| Unfavorable | 31 (57%) | 57% (48% – 67%) | |
| Age | |||
| ≤12 months | 14 (26%) | 35% (22% – 48%) | 0.11 |
| ≥12 months | 40 (74%) | 48% (39% – 58%) | |
| ≤18 months | 23 (43%) | 38% (27% – 49%) | 0.11 |
| ≥18 months | 31 (57%) | 50% (40% – 60%) | |
| MYCN and Shimada classification | |||
| Non-amp/favorable (intermediate risk) | 23 (43%) | 28% (19% – 37%) | < 0.001* |
| Non-amp/unfavorable (all but one are ≥ 12 month old) | 14 (26%) | 44% (33% – 56%) | |
| Amp/favorable | 0 | ||
| Amp/unfavorable (high risk) | 17 (31%) | 68% (57% – 79%) | |
| PTEN expression | |||
| Diffuse | 28 (53%) | 32% (23% – 42%) | < 0.001 |
| Focal or negative | 25 (47%) | 60% (51% – 69%) |
*P-value for non-amp/favorable vs. non-amp/unfavorable = 0.033.
P-value for non-amp/unfavorable vs. amp/unfavorable = 0.005.
P-value for non-amp/favorable vs. amp/unfavorable < 0.001.